# A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease

> **NCT06996223** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 316 (estimated)

## Conditions studied

- Aortic Stenosis
- PCSK9 Inhibitor
- Calcified Aortic Valve Disease

## Interventions

- **DRUG:** The Group A received PCSK9 inhibitor plus statin therapy

## Key facts

- **NCT ID:** NCT06996223
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-12-30
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06996223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06996223, "A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06996223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*